Positive Preclinical Data in Prostate Cancer

Summary by AI BETAClose X

CRISM Therapeutics announced positive preclinical data for its ChemoSeed platform in prostate cancer, demonstrating that sustained docetaxel administration killed 72% of prostate cancer cells, compared to 65% with intermittent dosing. The concentration of docetaxel needed to inhibit 50% of prostate cancer cells was 3.5nM for sustained administration versus 9.8nM for intermittent dosing. The company also successfully formulated docetaxel within the ChemoSeed platform, achieving sustained drug release over at least 28 days. CRISM has also been awarded a Collaborative Doctoral Partnership studentship with Ulster University to support the development of docetaxel-ChemoSeed.

Disclaimer*

UK 100

Latest directors dealings